Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial.
To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 x 10(6) to 109 x 10(6)24 h (P < .02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 10(6)/24 h for the 6 initially treated with drug (P < .02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P < .05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.
Dept. of Medicine, Baylor College of Medicine, Houston, TX 77030.
A C
AC
White
C L
CL
Chappell
C S
CS
Hayat
K T
KT
Kimball
T P
TP
Flanigan
R W
RW
Goodgame
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D003457:Cryptosporidiosis / Q000188:drug therapy*; D003967:Diarrhea / Q000188:drug therapy; D004311:Double-Blind Method; D005243:Feces / Q000469:parasitology; D006801:Humans; D008137:Longitudinal Studies; D010270:Parasite Egg Count; D010303:Paromomycin / Q000627:therapeutic use*; D011446:Prospective Studies
D010303:Paromomycin